Skip to main content

Table 2 Patient co-morbidities across DREAM, MENSA, SIRIUS, and MUSCA

From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

  Patients (N = 1878)
Any condition, n (%) 1569 (84)
Upper respiratory, n (%)  
 Any condition 1102 (59)
 Allergic rhinitis or hay fever 911 (49)
 Sinusitis 288 (15)
 Nasal polyps 293 (16)
Cardiovascular, n (%)  
 Any condition 620 (33)
  Arrythmia 49 (3)
 Cardiac failure 13 (< 1)
 Cardiomyopathy 4 (< 1)
 Coronary artery disease 48 (3)
 Hypertension 560 (30)
 Hyperglycemia 48 (3)
 Cerebrovascular disorder 7 (< 1)
 Thrombophlebitic event 4 (< 1)
Obesitya, n (%) 603 (32)
Gastroesophageal reflux, n (%) 400 (21)
Psychopathologies, n (%)  
 Any condition 326 (17)
 Anxiety 141 (8)
 Depression 149 (8)
 Mood changes 78 (4)
 Sleep disorders 158 (8)
Diabetes mellitus, n (%) 148 (8)
Vocal cord dysfunction, n (%) 14 (< 1)
  1. BMI body mass index
  2. aDefined as BMI > 30 kg/m2